GlassScriptPhysician profile
Rostislav D Barabash
NPI 1699700815
$3,889.55
in general payments reported to CMS, 2019-2025
22 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $582 · 2023: $848 · 2024: $883 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,799.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $970.85 | 2021-2025 | Rexulti |
| Abbvie INC. | $521.65 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $442.31 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $347.83 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $238.07 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $191.36 | 2021-2025 | Spravato, Invega Sustenna |
| Bausch Health US, LLC | $164.25 | 2021-2025 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $140.39 | 2022-2025 | Auvelity |
| Tris Pharma INC | $138.70 | 2023-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $133.39 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $119.21 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $105.77 | 2021 | |
| Indivior INC. | $82.24 | 2021-2024 | Perseris |
| Alkermes, INC. | $68.70 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $51.74 | 2022-2025 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $45.60 | 2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $30.90 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $29.99 | 2024 | Loreev Xr, Teriparatide |
| Owp Pharmaceuticals, INC. | $27.47 | 2023-2024 | Subvenite, Lamotrigine |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.37 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $13.20 | 2023 | Belsomra |
| Eisai INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rostislav Barabash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.